Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | WHR1 | P49842 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889593 | 0.87 | CNR2 (0.43) | CNR2 | |
| SCHEMBL23612212 | 0.85 | SCN10A (0.41) | SCN10AOPRK1DPP4WHR1CNR2 | |
| SCHEMBL3251915 | 0.84 | OPRK1 (0.48) | OPRK1 | |
| SCHEMBL3247164 | 0.82 | OPRK1 (0.47) | OPRK1 | |
| SCHEMBL23612156 | 0.82 | SCN10A (0.42) | SCN10AOPRK1DPP4WHR1CNR2 | |
| SCHEMBL31337782 | 0.79 | MBOAT4 (0.43) | SCN10ADPP4WHR1CNR2 | |
| SCHEMBL23612168 | 0.78 | SCN10A (0.39) | SCN10AOPRK1DPP4WHR1CNR2 | |
| SCHEMBL1760411 | 0.76 | SMO (0.44) | DPP4 | |
| SCHEMBL24993522 | 0.75 | DPP4 (0.40) | SCN10ADPP4CNR2 | |
| SCHEMBL31337786 | 0.74 | CRBN (0.39) | SCN10ADPP4WHR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076499-B1 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-7691863-B2 | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators | HOFFMAN-LA ROCHE INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2076499-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008040649-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | CNR2, CNR1, P2RY2 | SCN10A 1282/4885OPRK1 170/4885DPP4 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.